October 21 at 11:30 am
A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BPAX&item_id=4209619
New York
Additional information is available online at: www.biosantepharma.com
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin(TM) (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development.
Additional information is available online at: www.biosantepharma.com
A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BPAX&item_id=4209619
No comments:
Post a Comment